Lv4
480 积分 2021-04-22 加入
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results—Reply
2小时前
求助中
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
26天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
28天前
已完结
Biomarker Screening by LCMS and Liquid Chip Technology in Acute Aortic Dissection
1个月前
已完结
Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study
1个月前
已完结
[Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]
2个月前
已完结
Local Therapy for Oligometastatic Disease—Cart Before the Horse?
2个月前
已关闭
Benefit from LCT in oligometastatic NSCLC
3个月前
已完结
Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma
4个月前
已完结
EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells
4个月前
已完结
皖公网安备34019202002308
